Objective: To review the cognitive and behavioral features of the different atypical parkinsonian syndromes in which motor symptoms dominate early clinical symptomology: multiple systems atrophy (MSA), progressive supranuclear palsy (PSP), and corticobasal degeneration (CBD). The impact of cognitive and behavioral deficits on quality of life, associations between neuropsychological and neuropsychiatric findings and brain imaging, and cognitive and behavioral symptom management are also discussed. Method: A review of the available MSA, PSP, and CBD literature was conducted, with emphasis given to studies investigating the cognitive and behavioral features of the syndromes. Results: Although the three reviewed atypical parkinsonian syndromes share many similarities to each other and PD from a neuropsychological perspective, differences in prevalence and severity of cognitive impairment and patterns of performance on neuropsychological and neuropsychiatric measures exist in the research literature. Conclusions: Cognitive and behavioral features are early and pervasive aspects of MSA, PSP, and CBD.
Introduction
The term "parkinsonism" refers to a cluster of symptoms including tremor, gait disturbance, bradykinesia, and rigidity (Fahn, 1977) . Although idiopathic Parkinson's disease (PD) is by far the most common cause of parkinsonism, parkinsonism can also be associated with secondary or acquired sources (e.g., medication effects, head trauma, toxin exposure) and other neurodegenerative disorders (Jankovic, 2008) . In the 1970s, Dr. Stanley Fahn coined the term Parkinson-plus or atypical parkinsonism to describe a group of neurodegenerative disorders distinct from idiopathic PD but which nevertheless share some of its central features (Fahn, 1977) . These parkinsonian syndromes were classified as "atypical" due to the presence of clinical features of classic PD as well as features uncharacteristic of classic PD (e.g., early and severe autonomic disturbances in multiple system atrophy, eye movement abnormalities in progressive supranuclear palsy (PSP), and early postural instability and falls in both). For instance, in contrast to PD, all of the four hallmark characteristics of PD (i.e., tremor at rest, rigidity, akinesia and bradykinesia, and postural instability [represented by the mnemonic TRAP]) are not necessarily present in the atypical parkinsonian disorders. The atypical parkinsonian disorders are characterized by atrophy to multiple cortical and subcortical networks and account for up to 20% of all parkinsonisms (Potashkin, Santiago, Ravina, Watts, & Leontovich, 2012) .
The atypical parkinsonian disorders are often subdivided according to the type of protein that is abnormally deposited in the brain, with deposition site correlating with clinical feature (see a review by Levin, Kurz, Arzberger, Giese, & Höglinger, 2016) . Dementia with Lewy bodies (DLB) and multiple systems atrophy (MSA) are considered synucleinopathies because the implicated protein is alpha-synuclein. Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are considered tauopathies because the implicated protein is tau.
In DLB, alpha-synuclein is primarily deposited in neocortical neurons, with the cardinal clinical feature being dementia. Parkinsonism usually does not occur until after cognitive and other symptoms characteristic of a dementing condition are present. In MSA, alpha-synuclein is primarily deposited in cerebellum and brainstem oligodendrocytes and includes the main clinical feature of autonomic dysfunction combined with parkinsonism or cerebellar ataxia. PSP and CBD are primary tauopathies, with tau deposition damaging neurons, oligodendrocytes, and astrocytes. The cardinal clinical features of PSP are supranuclear vertical gaze palsy with early postural instability with falls and backward falls. Cardinal clinical features of CBD include asymmetrical parkinsonism with apraxia or cortical sensory disturbance. It is also becoming increasingly recognized that gaze palsy is present in a minority of people with CBD. At present, no disease-modifying therapy has been shown to be effective for any atypical parkinsonian syndrome, and treatment usually involves symptom management (Levin et al., 2016) .
In addition to more "typical" clinical features observed during a neurological or physical examination, cognitive and behavioral symptoms are often present in the early stages of all the atypical parkinsonian syndromes . Although the neuropsychological and neuropsychiatric profiles of the atypical parkinsonisms share a number of similarities to PD and to each other, differences nevertheless exist. In this paper, the cognitive and behavioral features of the different atypical parkinsonian syndromes in which motor symptoms dominate early clinical symptomology (i.e., MSA, PSP, and CBD) are reviewed. The impact of cognitive and behavioral deficits on quality of life, associations between neuropsychological and neuropsychiatric findings and brain imaging, and cognitive and behavioral symptom management are also discussed. This review will begin with a discussion of the synucleinopathy MSA and be followed by discussions of the two tauopathies in descending order of prevalence (i.e., PSP and CBD, respectively). (For a comprehensive review on the cognitive and behavioral features of DLB, see Fields, in press ). It should be noted that there are myriad other less common or less readily identifiable disorders that contain parkinsonism as a feature (Litvan, 2005) that are beyond the scope of this review.
Multiple Systems Atrophy

Overview
The term MSA was initially coined by Graham and Oppenheimer to describe a progressive disease characterized by parkinsonism, cerebellar ataxia, and idiopathic orthostatic hypotension (Dickson et al., 1999; Graham & Oppenheimer, 1969) . Multiple systems atrophy unified three previously distinct disorders that all shared a common feature of alpha-synuclein cytoplasmic inclusions (i.e., olivopontocerebellar atrophy, Shy-Drager syndrome, and striatonigral degeneration) (Papp, Kahn, & Lantos, 1989) . The first strongly supported epidemiological study of MSA came from the examination of the medical records of all patients aged 50-99 exhibiting parkinsonian features in Olmsted County, Minnesota, between the years of 1976 and 1990 (Bower, Maraganore, McDonnell, & Rocca, 1997) . Yearly incidence of MSA was estimated to be approximately 3.0 per 100,000 for people aged 50-99 and higher than previously thought. Median age of symptom onset and survival time was estimated at 66 and 8.5 years, respectively. The overall incidence rate of MSA was found to be higher in women than in men, but Bower and colleagues noted that this difference may have been due to the low number of patients and not reflective of the general MSA population.
This initial epidemiological study took place prior to the development of the first consensus diagnostic criteria (Movement Disorder Society Scientific Issues Committee Report [MDSSICR] ) (Gilman et al., 1999) . In the MDSSICR report, two categories of MSA were defined: MSA with predominant parkinsonism (MSA-P) and MSA with predominant cerebellar ataxia (MSA-C). A second consensus was published in 2008 to incorporate more direct clinical findings (Gilman et al., 2008) . In the US and Europe, MSA-P appears to be the most common variant and accounts for approximately 65% of MSA cases (Geser et al., 2005; Kollensperger et al., 2010; Wenning et al., 2013) . Interestingly, this pattern does not match the distribution of MSA cases in Japan. In Japan, MSA-C has been noted as the most common variant and accounts for over 80% of MSA cases (Yabe et al., 2006) . Genetic predisposition and environmental influences in the pathogenesis of the disease may lead to this difference, but future research is needed in this area (Ciolli, Krismer, Nicoletti, & Wenning, 2014) .
Cognitive Features
Although it is widely accepted that MSA leads to cognitive decline, debate exists about the level and severity of this decline, and dementia is not listed as a feature of MSA according to MDSSICR criteria. Support for the position that cognitive impairment is not severe in MSA exists. For instance, samples of people with MSA have not met Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for dementia (Kao et al., 2009 ) and have been noted as performing relatively well on measures of general cognitive ability (Bak, Crawford, Hearn, Mathuranath, & Hodges, 2005) and on mental status tests commonly used as bedside cognitive screening measures (e.g., Mini-Mental State Examination [MMSE: Folstein, Folstein, & McGugh, 1975] ) (Burk, Daum, & Rub, 2006; Fetoni, Soliveri, Monza, Testa, & Girotti, 1999; Kao et al., 2009 ). However, DSM-IV criteria for dementia specify that memory impairment must be present, and short dementia screens such as the MMSE are not sensitive to deficits in executive function and language (Mast & Gerstenecker, 2010) that are often exhibited by people with MSA . In addition, differing results have been found using DSM-IV dementia diagnostic criteria. In a sample of 58 people from Japan diagnosed with MSA (49 with MSA-C and 9 with MSA-P), 20% of the people with MSA-C met DSM-IV diagnostic criteria for dementia (Kitayama, Wada-Isoe, Irizawa, & Nakashima, 2009) . A subset of the sample exhibited cognitive symptoms prior to motor symptoms and were misdiagnosed with Alzheimer's disease (AD) during life. Mild dementia may also be present in some people with MSA-P, but cognitive symptoms are highly associated with disease duration (Chang et al., 2009) . (It should be noted that the requirement of memory impairment is not a criteria for dementia in the latest version of the DSM (i.e., DSM-V)).
Impairment on tests of verbal fluency and executive function is most common across both MSA subtypes. Over 40% of a sample of people with MSA were impaired on the Verbal Fluency subtest of Addenbrooke's Cognitive Examination (ACE: Mathuranath, Nestor, Berrios, Rakowicz, & Hodges, 2000) and 20% were impaired on the Dementia Rating Scale (DRS: Jurica, Leitten, & Mattis, 2001; Mattis, 1998) subtest that contains a verbal fluency component (DRS Initiation/Perseveration) (Bak et al., 2005) . Distinct patterns of verbal fluency deficits have been found in prior studies. Category fluency has been shown to be more impaired than phonemic/letter fluency (Bak et al., 2005; Kao et al., 2009) , and noun fluency has been shown to be particularly problematic in MSA-C (Burk et al., 2006) . In one study, semantic fluency was found to be worse in MSA than in PD (Kao et al., 2009) . However, in another study (Meco, Gasparini, & Doricchi, 1996) no differences in total verbal fluency (i.e., a combination of semantic and phonemic/letter fluency) were observed between striatonigral degeneration type MSA (likely corresponding to MSA-P) and PD. Dysarthria is common across MSA subtype (Frattali, & Duffy, 2005) and may contribute to slowed verbal fluency.
In addition to verbal fluency, performance is often poor on other tests sensitive to frontal/executive dysfunction. In a sample of 372 people with MSA, almost 32% were impaired on the Frontal Assessment Battery (FAB; Dubois, Slachevsky, Litvan, & Pillon, 2000) , and 20% were impaired on DRS-2 Initiation/Perseveration (Brown et al., 2010) . On a test of executive function and processing speed (i.e., Trail Making Test Part B [TMT-B; Reitan & Wolfson, 1993] ), people with MSA took more time to complete the test and made more errors than a cognitively normal comparison group, with MSA-C being slower than MSA-P (Chang et al., 2009 ). In other studies in which MSA was compared to PD, the MSA groups demonstrated more errors, perseveration, and response inhibition when completing the task (Kao et al., 2009; Meco et al., 1996) . On the Stroop interference test (another test commonly used to tap executive function) (Stroop, 1935) , people with MSA-C were slower than people with MSA-P, and both MSA groups were slower than healthy comparisons (Chang et al., 2009 ). In another study using the Stroop task, a sample of people with MSA was slower and exhibited poorer inhibition than a group of people with PD (Meco et al., 1996) .
Investigations into memory impairment in MSA vary. In a study in which MSA subtype was not specified, performances on measures of short-term verbal and visuospatial memory were similar to those of a sample of people with PD (Kao et al., 2009) . Despite exhibiting deficits in working memory similar to other parkinsonian disorders (Stankovic et al., 2014) , people with MSA demonstrate the ability to utilize a well-defined strategy when engaged in working memory tasks (Robbins et al., 1994) . Of the two MSA subtypes, people with MSA-C appear to have more prominent memory deficits, with impairments in both immediate and delayed verbal memory being noted (Balas, Balash, Giladi, & Gurevich, 2010; Burk et al., 2006; Chang et al., 2009) .
Deficits in processing speed and attention are also present in some people with MSA. People with MSA have been shown to possess poorer attentional set shifting and to exhibit slower thinking time prior to initial engagement in a task requiring a set strategy (Robbins et al., 1994) . People with MSA perform similar to healthy comparisons on basic attention tasks such as Digit Span Forwards and similar to people with PD on attention tasks that contain a working memory component such as Digit Span Backward (Chang et al., 2009) . People with MSA-C perform more poorly than people with MSA-P on tests of executive functioning that contain an attentional component (Chang et al., 2009; Kao et al., 2009; Kawai et al., 2008) .
Regarding other cognitive domains, visuospatial ability was poorer in MSA than in PD in one study (Kao et al., 2009 ) but similar to a healthy comparison group in another study that included only the MSA-C subtype (Burk et al., 2006) . In the latter study, it should be noted that the MSA-C group was younger and had a shorter disease duration than the MSA sample used in the first study. Although visuospatial and constructional skills were worse in MSA-P than in MSA-C in another study, both MSA subtypes fell short of healthy comparisons (Kawai et al., 2008) . Conceptual thinking skills are similar to PD, and confrontational naming remains relatively intact (Kao et al., 2009; Meco et al., 1996) .
The effect of cognition on quality of life in MSA has not been well studied. Both quality of life and cognition were assessed in a sample of 10 people with MSA and in a sample of 10 people with PD who were matched for motor disability (Torny et al., 2009) . Overall, quality of life was similar between MSA and PD. However, people with MSA did indicate lower scores on a subscale of the quality of life measure related to vitality. In the MSA group, only scores on Stroop interference were associated with quality of life (i.e., vitality).
Neuropsychiatric Features
MSA is associated with a number of neuropsychiatric/behavioral features. Depression is particularly prominent and has, on rare occasion, been reported to be the initial symptom of the disorder (Goto et al., 2000) . However, rates of depression vary widely in the MSA research literature, with estimates ranging from 10%-80% (Benrud-Larson, Sandroni, Schrag, & Low, 2005; Fetoni et al., 1999; Kao et al., 2009; Kawai et al., 2008) . In one study, a self-report depression inventory (i.e., Beck Depression Inventory [BDI]: Beck & Beamesderfer, 1974) was completed by 99 people with MSA between 1998 (Benrud-Larson et al., 2005 . Of the 99 people with MSA, 79 (about 80%) self-reported significant levels of depressive symptoms. This estimate was noted by the study authors as being higher than is commonly reported in PD samples. Of depressed patients, 51% exhibited mild depression, 39% moderate depression, and 10% severe depression. Mean BDI scores were higher for people with MSA-C than for people with MSA-P, but the difference did not reach statistical significance. Suicidal ideation was present in only 5% of the study sample.
However, rates of depression were higher in the study by Benrud-Larson and colleagues than in previous studies. Although the study authors noted that this may indicate that rates of depression are higher in MSA than previously thought, they nevertheless noted that depression estimates may have been affected by the use of a self-report measure in combination with a low overall response rate of approximately 50%. In other studies, estimates of depression range from approximately 10%-50% and are consistently noted as being lower than in PD (Fetoni et al., 1999; Kao et al., 2009; Kawai et al., 2008) . Differences across MSA subtype are also noted in the MSA research literature. As previously stated, Benrud-Larson and colleagues did not find a significant difference in depression between the two MSA subtypes but did report higher mean BDI scores for people with MSA-C. However, depression was noted as more severe in MSA-P in another study (Balas et al., 2010) . Although a significant difference between depressive symptoms in MSA-C and MSA-P was not observed, Balas and colleagues found that people with MSA-P exhibited significantly more symptoms of severe depression than did the healthy comparison group. Differences of depression severity only approached significance when people with MSA-C were compared to the healthy comparison group. Regardless, depression is a common feature in MSA, and screening for depressive symptoms should be part of an initial evaluation when working with people with MSA .
Depression in MSA has a number of clinical correlates. Depression and cognitive impairment (particularly executive dysfunction and short-term memory) have been shown to be related, but blunted affect and indifference may be more common than depression in people with MSA with less cognitive decline (Fetoni et al., 1999) . Results of positron emission tomography with 18F-fluorodeoxyglucose (FDG-PET) have revealed associations between depressive symptoms and decreased regional glucose utilization in left superior and middle frontal areas (Herting et al., 2007) . In the same study, decreased glucose utilization in left dorsolateral prefrontal cortex was associated with the severity of depression.
People with MSA also exhibit more symptoms of anxiety than do healthy comparisons; however, anxiety symptoms are less common and severe than in PD or DLB (Balas et al., 2010; Chang et al., 2009; Kao et al., 2009) . In general, anxiety may be more pronounced in MSA-C than in MSA-P (Balas et al., 2010; Chang et al., 2009 ), but the manner in which anxiety symptoms are manifested may vary between the two MSA subtypes. In a study of 15 people with MSA-P and 10 people with MSA-C, both state (i.e., anxiety in relation to a current stressor) and trait (i.e., a more enduring aspect of personality and way of reaction) anxiety were elevated in the MSA-P group (Balas et al., 2010) . The MSA-C group, on the other hand, exhibited only elevated levels of state anxiety. In addition, state anxiety and disease duration were associated only in the MSA-C group.
In addition to depression and anxiety, other neuropsychiatric symptoms are exhibited by some people with MSA. Using the neuropsychiatric inventory (NPI) (Cummings et al., 1994) Kao and colleagues evaluated behavioral changes in a group of people with MSA (Kao et al., 2009) . Neuropsychiatric symptoms were present in a majority of the MSA group and-in addition to depression (50%) and anxiety (33%)-included apathy (40%), irritability (20%), hallucinations (20%), agitation (10%), and disinhibition (10%). Appetite and eating changes and repetitive motor behavior were noted in 30% and 20%, respectively. In a later study, NPI scores were slightly more elevated: depression (56%), apathy (48%), anxiety (27%), agitation (27%), hallucination (14%), disinhibition (12%), and irritability (10%) (Ceponiene et al., 2016) . At least some level of neuropsychiatric symptomology was present in 87% of the MSA sample.
A review of the neuropsychiatric features of any parkinsonian-related disorder would not be complete without some discussion of the apathy versus depression debate. Since depression includes features of apathy, some claim that apathy and depression may represent a single construct (Levy et al., 1998) . However, others believe apathy and depression represent distinct clinical syndromes. Empirical investigations on the topic have been conducted in PD, with evidence supporting the position that apathy and depression are distinct (Kirsch-Darrow, Fernandez, Marsiske, Okun, & Bowers, 2006; Kirsch-Darrow, Marsiske, Okun, Bauer, & Bowers, 2011) . However, similar studies have yet to be conducted in large samples of people with an atypical parksinsonism. This has led to suggestions that base rates of depression are inflated in the atypical parkinsonian syndromes. Pseudobulbar affect (i.e., pathological laughing and crying) is also present in some people with an atypical parkinsonism (Parvizi, Joseph, Press, & Schmahmann, 2007; Strowd, Cartwright, Okun, Haq, & Siddiqui, 2010) and can lead to caregivers mistakenly believing his/her loved one is depressed.
Sleep disorders affect up to 40% of people with MSA (Gilman et al., 2005; Kao et al., 2009 ) and sleep quality decreases as the disease progresses (Gama et al., 2010) . REM sleep behavior disorder (i.e., acting out dreams) is particularly common in MSA and has even been noted as the initial symptom of the disease (Iranzo et al., 2005; Santamaría & Iranzo, 2008) . Vivid dreams are reported by about half of people with MSA and almost a third experience excessive daytime sleepiness (Gilman et al., 2005; Moreno-López et al., 2011) . The main contributing factors of excessive daytime sleepiness are poor sleep efficiency (i.e., ratio of total time spent asleep to the total amount of time spent in bed) and disordered breathing while sleeping; however, restless legs syndrome (RLS) also contributes (Gama et al., 2010; Moreno-López et al., 2011) .
Treatment of Cognitive and Neuropsychiatric Features
No treatments have been shown to increase survival time in MSA, and therapeutic strategies focus on symptom management (for a review see Perez-Lloret et al., 2015) . At present, empirical evidence about the efficacy of a therapeutic strategy for cognitive dysfunction in MSA is not available. Depression is prevalent in MSA and associated with poorer reported quality of life. Antidepressant use (particularly SSRIs) is common in MSA, but increased autonomic symptoms and disease severity were associated with antidepressant use in a French study (Colosimo, Albanese, Hughes, de Bruin, & Lees, 1995) . In general, antidepressants have not been found to be effective for apathy and may even worsen apathy for some (Barnhart, Makela, & Latocha, 2004) . Antiparkinsonian treatments are not as effective for depression in MSA as they are in PD but may be more effective for those exhibiting depressive symptoms early in the course of the disease (Fetoni et al., 1999; Goto et al., 2000) . For treatment-resistant depression, electroconvulsive therapy (ECT) may be useful (Shioda, Nisijima, & Kato, 2006) .
For REM sleep behavior disorder, it is recommended that the bed environment be secured (e.g., removing hazards, lowering bed) (Coeytaux, Wong, Grunstein, & Lewis, 2013) . REM sleep behavior disorder may be responsive to clonazepam (Santamaría & Iranzo, 2008) , but benzodiazepines may aggravate existing obstructive sleep apnea (OSA) and increase the risk of nighttime falls (Perez-Lloret et al., 2015) . Melatonin may also be helpful for REM sleep behavior disorder, but more research is needed in the area (Perez-Lloret et al., 2015) . Consensus-based recommendations are available for the treatment of RLS (Garcia-Borreguero et al., 2013) , but trials have not been conducted in MSA samples (Perez-Lloret et al., 2015) .
Progressive Supranuclear Palsy
Overview John Steele, J Clifford Richardson, and Jerzy Olszewski first described PSP as a distinct syndrome in 1963 following Richardson's clinical observations on several patients evaluated in Toronto in the late 1950s (Morris, Wood, & Lees, 1999; Steele, 1994; Steele, Richardson, & Olszewski, 1964) . As with MSA, the first well supported epidemiological evaluation of PSP came from the Olmsted County database study (Bower et al., 1997) . Annual incidence rates of 5.3 per 100,000 were found, and incidence estimates increased dramatically with age (i.e., 1.7 per 100,000 at ages 50-59 vs. 14.7 per 100,000 at ages 80-99). PSP symptom onset typically occurs in the fifth to seventh decade of life, with most people developing symptoms in their mid-60s. However, about a third of all people with PSP experience symptom onset prior to age 60. Median survival time is 5.6 years, and people with the disorder rarely survive longer than 10 years from symptom onset.
Several PSP phenotypes have been described, the most common being the phenotype associated with the classical clinical description and thus named by some as PSP-Richardson's syndrome (RS). Richardson's syndrome is characterized by early postural instability and falls during the first year, axial parkinsonism not responding to levodopa therapy, and vertical supranuclear palsy or slowing of vertical saccades. In 1996, the National Institute of Neurological Disorders and Stroke (NINDS) and the Society for PSP (SPSP) published criteria for the diagnosis of classical PSP with greater predictive validity than previously existing criteria (Litvan, Agid, et al., 1996 , Litvan, Hauw et al., 1996 .
Other PSP phenotypes exist and research criteria are being developed to better diagnose and describe the non-RS PSP phenotypes. In a blog post by Dr. Lawrence Golbe (Professor of Neurology at Rutgers Wood Johnson Medical School and Director of Research and Clinical Affairs at CurePSP), some insight is given about these new diagnostic criteria: "A year ago we started to hash things out by email and conference calls, using the published articles on clinical features of PSP that use either autopsy or the NINDS-SPSP Criteria as a gold standard. The group, comprising 33 people from 11 countries, met in Munich on March 9 and 10 to turn our rough draft into a final version suitable for submission to a journal for peer review. The new criteria recognize the various phenotypes of PSP. They are PSP-Richardson syndrome (about 55% of all PSP), PSPparkinsonism (30%), PSP-frontal dementia (5%), PSP-ocular motor (1%), PSP-pure akinesia with gait freezing (1%), PSPcorticobasal syndrome (1%), PSP-progressive non-fluent aphasia (1%), and PSP-cerebellar (<1%). The remaining few percent are combinations of these or still-unrecognized forms." (Golbe, 2016) .
Cognitive Features
In contrast to MSA, there is general consensus that cognitive impairment is a prevalent and prominent aspect of PSP. In the two largest studies of cognition in PSP to date, neuropsychological batteries were administered to samples of 311 and 200 people diagnosed with PSP (Brown et al., 2010; Gerstenecker, Mast, Duff, Ferman, & Litvan, 2013) . In the study by Brown and colleagues, approximately 57% of the sample exhibited impairment on the Total score of the DRS-2 (i.e., a measure of general cognitive function), and about 80% exhibited impairment in at least one cognitive domain. In the study by Gerstenecker and colleagues, 49% of the sample exhibited impairment on DRS-2 Total, and about 85% exhibited impairment in at least one cognitive domain. Interestingly, the high rate of impairment was observed despite scores of >24 on the MMSE being required for study inclusion. Thus, the authors concluded that rates of cognitive impairment were likely higher in the general PSP population. The results of the study by Gerstenecker and colleagues were largely confirmed in a conference paper in which data for the full ENGENE-PSP sample (N = 350) were presented (Gerstenecker, Triebel, & Litvan, 2015) .
Similar to MSA, frontal/executive features dominate the neuropsychological profiles of people with PSP . On the DRS-2, the characteristic PSP profile has been described as performance on the Initiation/ Perseveration subscale being poorer than performance on the Memory subscale (Brown et al., 2010; , and this pattern has been shown to distinguish PSP and AD samples (Aarsland et al., 2003) . On a measure designed to tap frontal/executive function (i.e., FAB), 70%-90% of people with PSP score in the impaired range (Brown et al., 2010; Kaat et al., 2007) .
Impairment is common on tests of verbal fluency, and distinct patterns of verbal fluency performances have been noted when evaluating PSP samples. On the DRS or DRS-2 subtest that contains a category fluency component (i.e., Initiation/ Perseveration), impairment ranges from 55%-73% (Brown et al., 2010; , with performance being lower when compared to PD (Aarsland et al., 2003) . Although performance on category fluency tasks is impaired, performance on tasks of letter/phonemic fluency has been shown to be more impaired (Bak et al., 2005) . On tasks of letter/phonemic fluency, up to 50% of people with PSP name fewer than three words, 80% fewer than five words, and 85% fewer than nine words (Kaat et al., 2007) . In regards to action versus object naming, the discrepancy between the two (action worse than object naming) is greater than in some variants of frontotemporal dementia (FTD) (Bak et al., 2005; Cotelli et al., 2006) . Clinical correlates of verbal fluency have been noted in the PSP research literature. Disease duration has not been shown to be correlated with verbal fluency but both the ability to perform the applause sign (the ability to mimic a handclapping sequence) (Kaat et al., 2007) The effects of PSP on learning and memory are not well understood. Given the involvement of frontal networks in the disease, it has been suggested that memory retrieval may be more affected than memory encoding. On the DRS Memory subtest, people with PSP have been shown to outperform AD samples (Aarsland et al., 2003) . However, reliable inferences about retrieval versus encoding require the use of more comprehensive tests of memory that include both free recall and recognition components.
By administering the California Verbal Learning Test-Second Edition, Short Form (CVLT-II SF) to a large sample of people with PSP, Gerstenecker and colleagues attempted to help clarify debate about memory in PSP . Results showed that-consistent with neuropathological (Litvan, Agid, et al., 1996) and neuroimaging (Blin et al., 1990 ) findings-memory deficits in PSP may be more a function of striatofrontal dysfunction than to hippocampal atrophy. Overall, the performance of the PSP sample fell in the low average to average range. However, depending on CVLT-II SF index, 16%-25% of the sample exhibited at least some level of memory impairment. When analyzing the pattern of impairment, a typical "subcortical" memory profile (Bonelli & Cummings, 2008) was not observed. Whereas subcortical dementias are expected to present with retrieval deficits (Duff, Beglinger, Theriault, Allison, & Paulsen, 2010) , the PSP group demonstrated relatively strong short and long delayed free recall with minimal benefit from cueing. However, significant dissociation between delayed recall and recognition discrimination indicated that some level of retrieval deficit was present.
Other cognitive domains are also implicated in PSP. Impairment on DRS or DRS-2 Attention is not common (Aarsland et al., 2003; Brown et al., 2010; , and this may indicate that performance on basic attention tasks is relatively well preserved in PSP. However, on more complex attention measures that contain visual scanning or set shifting components, people with PSP lag behind people with PD (Robbins et al., 1994; Soliveri, 2000) and show significant decline at a 21-month follow-up (Soliveri, 2000) . People with PSP also experience more difficulty than people with PD on tests of visual-spatial orientation (Soliveri, 2000) .
Neuropsychiatric Features
Neuropsychiatric features are pervasive in PSP, similar to dementias of the frontal lobe, and associated with atrophy to frontal brain areas (Cordato et al., 2002) . Negative behavioral features (e.g., apathy, aspontaneity, indifference) are more common than positive behavioral features (e.g., irritability, social inappropriateness, impulsivity). Apathy is particularly common in PSP and estimates range between 57% and 90% (Aarsland, Litvan, & Larsen, 2001; Borroni, Alberici, Agosti, Cosseddu, & Padovani, 2009; Litvan, Mega, Cummings, & Fairbanks, 1996) . Apathy is more common in PSP than in PD even after controlling for disease duration, disease severity, antiparkinsonian medication use, age, and gender (Aarsland et al., 2001) . High levels of apathy with accompanying low levels of agitation and anxiety can be used to differentiate PSP from AD up to 85% of the time (Litvan, Mega, et al., 1996) Although less common and severe than in PD (Aarsland et al., 2001) , depression is common in PSP and associated with decreased glucose utilization in bilateral middle frontal cortex, left and right superior frontal gyrus, and right middle frontal gyrus (Herting et al., 2007) . Debate exists about whether depression and apathy represent distinct neuropsychiatric features (please see discussion in MSA section), but the results of a study of a large sample of people with PSP may provide some insight . While depression and apathy were common in the sample (i.e., 58% and 62%, respectively), the two behavioral features were not statistically correlated and shared only 1% of variance. Of the 154 people with PSP comprising the sample, only 13 (8.4%) were rated as exhibiting moderate to severe symptoms of both depression and apathy. Furthermore, anxiety is commonly associated with depression but not apathy, and this association was observed in the study. Given these observations, the study authors concluded that depression and apathy are distinct in PSP . It should be noted that rates of depression in the study by Gerstenecker and colleagues may have been slightly elevated due to 14 people being rated as depressed by caregivers, who, more than likely, should have been rated as showing emotional lability or pseudobulbar affect.
Other behavioral abnormalities also occur in PSP. In the study by Gerstenecker and colleagues, over a third of the sample had elevated levels of disinhibition, agitation, irritability, or disrupted eating patterns. Less frequent behavioral features included anxiety (23.9%), elation/euphoria (13.5%), hallucinations (12.2%), and delusions (11%).
In contrast to previous studies (Aarsland et al., 2001; Borroni et al., 2009; Litvan, Mega, et al., 1996) , behavioral features were not associated with executive dysfunction in the study by Gerstenecker and colleagues. Conversely, attention and memory showed mild associations with some NPI variables. Thus, although some overlap may be present between behavioral abnormalities and cognition due to the parallel disruption of neural connections mediating these processes, behavioral abnormalities and cognition may be largely independent in PSP. Given these observations, the authors concluded that interventions aimed at addressing one set of symptoms (e.g., motor) may not affect other symptoms (e.g., neuropsychiatric) in PSP. However, more research is needed on this topic.
Sleep disorders are common in PSP and more prevalent than in PD (Gama et al., 2010) . Overall, increased sleep latency is the main contributor to poor sleep, but elevated levels of RLS and OSA also play a role (Gama et al., 2010) . Not surprisingly, people with PSP often suffer from excessive daytime sleepiness with daytime fatigue worsening as the disease progresses (Gama et al., 2010) . Disparate in the other atypical parkinsonisms, REM sleep behavior disorder is not typical (Cooper & Josephs, 2009 ).
Treatment of Cognitive and Neuropsychiatric Features
No treatment has been shown to increase survival, hospitalization rate, or quality of life in PSP, so therapeutic strategies focus on symptom management (for a review see Hajjar & Cooper, 2016) . Rittman, Coyle-Gilchrist, and Rowe recently reviewed the management of cognitive impairment in PSP (Rittman, Coyle-Gilchrist, & Rowe, 2016) and listed several practice points about medication use: (i) side effects of levodopa can worsen cognition, (ii) amantadine can be helpful to improve some cognitive features but has negative side effects, (iii) anticholinergic medications should be used with caution due to cognitive side effects, and (iv) antidepressants should be chosen over antipsychotics. Rittman and colleagues note that behavioral interventions are likely to be the best approach but that specific studies of cognitive rehabilitation in PSP are not available.
The treatment of depression in PSP should be executed with caution because a failure to disentangle depression from apathy often leads to the unnecessary use of antidepressant medication. Although SSRIs can be used for depression and apathy, clear benefit has not been empirically demonstrated in PSP (Koros & Stamelou, 2016) . In addition, in general, antidepressants have not been found to be effective for apathy and may even worsen apathy for some (Barnhart, Makela, & Latocha, 2004) . However, SSRIs have been shown to reduce behavioral features and response inhibition in people with FTD (Huey, Putnam, & Grafman, 2006; Hughes, Rittman, Regenthal, Robbins, & Rowe, 2015) . Improvement of depressive symptoms in a woman with PSP taking tricyclic antidepressant medication has been noted in a published case report (Tamai, Almeida, & de Idosos, 1997) , but use of this class of medication may lead to a number of adverse side effects in PSP (Nieforth & Golbe, 1993) . Trazodone may be beneficial as a sleep aid and is well tolerated in other neurodegenerative disorders (Houlihan et al., 1994; Sultzer, Gray, Gunay, Berisford, & Mahler, 1997) . Also, mirtazapine may be of benefit in PSP through its promotion of sleep maintenance and weight (Rittman et al., 2016) .
Corticobasal Degeneration
Overview
Corticobasal degeneration was initially presented in a paper (i.e., "Corticodentatonigral degeneration with neuronal achromasia") that described three patients with slow and awkward voluntary limb movement, tremor, dystonic posturing, stiffness, lack of dexterity, numbness or deadness of the affected limb, and gait disorder (Mahapatra, Edwards, Schott, & Bhatia, 2004; Rebeiz, Kolodny, & Richardson, 1968) . Corticobasal degeneration is a challenging syndrome to diagnose clinically, and pathologic studies have shown that the original clinical descriptions of CBD often corresponded to PSP, AD, or FTD (Armstrong et al., 2013) . Thus, a distinction can be drawn between the classical clinical presentation of CBD (termed corticobasal syndrome [CBS] ) and pathologically confirmed CBD. Corticobasal degeneration is especially rare and few epidemiologic studies exist. Symptom onset most commonly occurs in the sixth to seventh decades of life, with an average onset at age 63 (Wenning et al., 1998) . Severe disability and death usually occur within 10 years of symptom onset.
Initially, cognitive dysfunction, dementia, and severe behavioral changes were not thought to be common in CBD. However, the understanding of CBD has evolved considerably since the initial description by Rebeiz and colleagues. As research into CBD began to expand, a need developed for standardized criteria that could be used to classify study subjects. This need led to the publication of suggested clinical features (Litvan et al., 1997; Rinne, Lee, Thompson, & Marsden, 1994) . Although the publication of clinical features was an important step forward, the clinical features relied almost exclusively on motor deficits. Thus, while achieving greater specificity in the selection of CBD subjects, those people with CBD who did not present with primary motor deficits were largely missed. Nevertheless, study results began to show that CBD included both cognitive and behavioral aspects. This led to debate about the possibility of heterogeneous presentations in CBD and to speculation that at least two phenotypes of CBD may exist: lateralized CBD and the dementia phenotype (Moretti, Torre, Antonello, Cattaruzza, & Cazzato, 2005; Murray et al., 2007) .
In 2013, the first set of diagnostic criteria was published for CBD (Armstrong et al., 2013) . Four CBD phenotypes were listed: corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), non-fluent/agrammatic variant of primary progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS). However, as noted by Armstrong and colleagues, the diagnosis of CBD remains difficult: "In light of advances in the understanding of CBD, we used specialist consensus, brain bank cases, and a critical literature review to develop new diagnostic criteria. During this process, however, it became clear that clinicopathologic heterogeneity of CBD confounds the development of specific criteria, unlike what has been accomplished for other neurodegenerative diseases. Thus, we propose two sets of criteria: a narrower, more specific one for probable CBD and a broader set for possible CBD that has less specificity for CBD pathology while still representing probable tau-based pathology" (pg. 497). "Ultimately, a clear diagnosis of CBD may only be possible once biomarkers and associated genetic mutations are identified" (pg. 501).
A clear understanding of the evolution of CBD clinical and diagnostic criteria is needed to become an informed consumer of the research literature on cognitive and behavioral features of CBD. As previously discussed, early investigations into CBD utilized clinical criteria based on the classical clinical description of the disorder. As such, samples were composed almost entirely of people with CBS and resulted in inaccurate views on the cognitive and behavioral features of the disorder. These views were later challenged and differing phenotypes of CBD proposed. Thus, research began to focus more heavily on cognitive and behavioral changes in CBD and to examine the two proposed phenotypes (i.e., lateralized CBD and the dementia phenotype). Although these investigations have led to the acceptance that significant cognitive and behavioral changes are present in many people with CBD, the proposed phenotypes were not included in the four phenotypes listed in the Armstrong criteria.
In the following sections, research about the cognitive and behavioral features of CBD will be reviewed. Only studies of pathologically confirmed CBD will be included in this review. We acknowledge that this method of study inclusion is more restrictive than a clinical perspective but encourage research into the cognitive and behavioral features of CBD using the Armstrong criteria. (For a review of cognitive and behavioral features of CBS, please see .
Cognitive Features
Studies of neuropsychological features in autopsy-proven CBD are rare. Regardless, cognitive impairment and dementia have been noted as a central feature in studies of CBD that offer pathological confirmation. In one study, dementia was even shown to be the most common clinical feature of the disease (Grimes, Lang, & Bergeron, 1999) . Similar to both MSA and PSP, performance is particularly poor on tests of verbal fluency and other measures designed to tap executive functioning (Murray et al., 2007; Vanvoorst et al., 2008) . Although declining over time, confrontational naming and verbal comprehension are initially comparable to healthy comparisons (Murray et al., 2007) . Subjective memory complaints are common in CBD, but episodic memory was found to be relatively well preserved in one study (Murray et al., 2007) . However, memory impairment has been noted in studies in which patients were clinically diagnosed as AD or atypical AD but were later found to have CBD (Armstrong et al., 2013; Ling et al., 2010) . Visuospatial skills lag behind healthy peers but have been shown to be superior to a sample of people with other neurological disorders (i.e., frontotemporal lobar degeneration with ubiquitinpositive inclusions [FTLD-U, n = 10], AD[AD, n = 8], frontotemporal dementia with parkinsonism due to a mutation on chromosome 17 of the region coding tau [FTD-17, n = 1], Pick's disease [PiD, n = 1], and argyrophilic grain disease [AGD, n = 1]) (Murray et al., 2007) .
Neuropsychiatric Features
Similar to studies of cognitive features, studies examining the neuropsychiatric features of CBD are rare. In such studies, similar to PSP, behavioral features in CBD resemble those of people with dementias of the frontal lobe. For example, in a retrospective chart review, behavioral features were assessed at two time points: the first visit (i.e., average of 3 years from symptoms onset) and the last visit (i.e., average of 6 years from symptoms onset) (Wenning et al., 1998) . At the first visit, 21% of the study sample exhibited behavioral features with apathy, irritability, and disinhibition being most common. At the last visit, 58% exhibited behavioral changes.
In a later, more comprehensive study of behavioral changes in pathologically confirmed CBD, 22% of the sample exhibited behavior changes often associated with disruptions to the frontal lobe (i.e., disinhibition, impulsivity, obsessive-compulsive behaviors, and depression) (Geda et al., 2007) . Geda and colleagues noted that the behavioral manifestations of the CBD group could be divided into three syndromes based on diagnoses applied during life: primary progressive aphasia (PPA/FTD), FTD, and CBS. Initial behavior changes were not common in the PPA/FTD group. However, as the disease progressed, inappropriate social behaviors and disinhibition emerged. For the group diagnosed with FTD during life, irritability, indecision, and somnolence were present early. As the disease further progressed, impulsivity increased, judgment became more impaired, and aggressive tendencies became more profound. One person even attempted to strangle his wife and was eventually transferred to a long-term care facility. For the CBS group, 50% exhibited depressive symptoms, and 50% exhibited compulsive behaviors. None of the sample experienced visual hallucinations, and Geda and colleagues stated that the absence of visual hallucinations may help to distinguish CBD from other parkinsonian syndromes. The authors also noted that apathy may not have been adequately assessed in the study sample. Thus, rates of behavior changes in CBD were likely underestimated.
To our knowledge, studies of sleep changes in pathologically confirmed samples of people with CBD are not available. However, people with CBD may complain of significant sleep-related circadian disturbances and daytime fatigue (Jennum et al., 2010) .
Treatment of Cognitive and Neuropsychiatric Features
Similar to MSA and PSP, effective treatments for CBD are lacking, and therapeutic strategies focus on symptom management (see Armstrong, 2014 for a review). However, given the lack of studies in CBD, treatment options are based on evidence from other disorders (Armstrong, 2014) . In people with FTD, donepezil use has been shown to be associated with adverse behavioral changes (Mendez, Shapira, McMurtray, & Licht, 2007) , and discontinuation of the medication has been associated with behavioral improvements and decreased caregiver burden (Kimura & Takamatsu, 2013) . Galantamine has shown slight effects for people with PPA but not for people with behavioral variant FTD (Kertesz et al., 2008) . As noted in the review by Armstrong, it is likely that treatment response is associated with underlying pathology. Thus, Armstrong recommends: "Given the current uncertainty in correctly identifying the pathologic diagnosis in patients presenting with CBS and other phenotypes associated with CBD, it may be reasonable to try AChEIs given that patients with certain underlying pathologies like AD may experience some improvement" (pg. 286). Memantine has been shown to have no benefit in FTD (Boxer et al., 2013 (Boxer et al., , 2009 Diehl-Schmid, Forstl, Perneczky, Pohl, & Kurz, 2008) but is listed as investigational for the treatment of cognition in PD (Seppi et al., 2011) . SSRIs and/or cognitive behavioral therapy may be useful for depression, anxiety, and obsessive-compulsive features in CBD (Boeve, Josephs, & Drubach, 2008 ) but can worsen apathy, which is particularly difficult to treat (Armstrong, 2014) .
Conclusion, Differential Diagnosis, and Recommendations for Neuropsychological Assessment of Atypical Parkinsonian Disorders
The atypical parkinsonian syndromes describe a group of neurodegenerative disorders distinct from idiopathic PD but share the central features of tremor, gait disturbance, bradykinesia, and rigidity (Fahn, 1977) . In this paper, it was shown that cognitive and behavioral features are early and pervasive aspects of MSA, PSP, and CBD. Although the three reviewed atypical parkinsonian syndromes share many similarities to each other and to PD from a neuropsychological perspective, differences in prevalence and severity of cognitive impairment and patterns of performance on neuropsychological and neuropsychiatric measures exist in the research literature.
At present, clinicopathologic confirmation is required for a definitive diagnosis of an atypical parkinsonian syndrome. During life, upwards of 60% of people with an atypical parkinsonism are initially misdiagnosed (Williams & Lees, 2009) , with PD being the most commonly misapplied diagnosis . In general, accurate diagnosis of an atypical parkinsonism during life requires examination by a movement disorder neurologist (Hughes, Daniel, Ben-Shlomo, & Lees, 2002) . However, even for movement disorder specialists, differential diagnosis can be difficult early in the course of the disease (Abdo et al., 2006) .
In a review, Lees, Williams, and Storey (2012) investigated the ability of cognitive testing to aid in the differential diagnosis of parkinsonian syndromes. In general, cognitive testing was not found to be highly useful in separating MSA from PD. However, poorer performance for MSA did show some utility for the following cognitive tests: TMT-B time (d = 1.63), TMT-B errors (d = 1.86), and errors on the Stroop test (d = 1.82). Cognitive testing was found to be more useful in differentiating PSP from PD. For example, performance on tests of phonemic/letter fluency, category fluency (particularly alternating category fluency), errors on the Wisconsin Card Sorting Test (WCST; Heaton, 1981) , TMT-A time, TMT-A errors, and total score on the Frontal Assessment Battery were shown to be useful in separating PSP from PD (performance poorer for PSP). For differentiating PSP from MSA, poorer semantic fluency, phonemic/letter fluency, and poorer performance on the WCST were all found to be useful. The authors noted that cognitive testing alone is not adequate to distinguish PSP subtype. The only cognitive feature that reliably separated CBS from other parkinsonian disorders was the presence of severe oro-buccal apraxia, which can be assessed by asking patients to perform oro-buccal gestures such as licking lips or coughing (Burrell, Hornberger, Vucic, Kiernan, & Hodges, 2014) . The authors noted that "the role of cognitive testing in predicting pathologies other than AD causing CBS is very limited at present" (pg.1252).
Recommendations for choosing a neuropsychological battery when working with people with an atypical parkinsonian disorder are provided. As with any cognitive assessment in an older adult population, measures of general cognitive function and premorbid intelligence should be administered. Across the three reviewed atypical parkinsonian syndromes, verbal fluency deficits are particularly common. Thus, any neuropsychological evaluation of these patients should include measures of verbal fluency. In addition, the inclusion of different types of verbal fluency tests (e.g., semantic fluency, letter/phonemic fluency, noun fluency, verb fluency) may help to differentiate syndrome and phenotype in some cases. Performance has also been shown to be poor on other tests of executive/frontal function, so measures tapping response inhibition, set shifting, and mental flexibility are also recommended. The use of executive measures that include an untimed motor component may be especially useful (e.g., FAB).
Despite debate existing about the nature of memory disturbances in the atypical parkinsonisms, the administration of a comprehensive memory test (e.g., CVLT-II SF) will likely provide insight about not only the severity of memory impairment but also the extent it reflects retrieval versus encoding deficits. Attention is not as problematic in the atypical parkinsonian disorders. However, people with CBD tend to perform more poorly than do people with PSP or MSA on DRS-2 Attention . Similar to attention, visuospatial deficits are not as problematic in MSA, PSP, or CBD (as opposed to DLB), so a comprehensive evaluation of this cognitive area is not often required. Language skills other than verbal fluency (e.g., confrontation naming) are relatively well preserved in MSA, PSP, and CBD.
An understanding of behavioral changes should be gathered when evaluating people with an atypical parkinsonism. Behavioral features not only affect the patient's quality of life but also contribute to caregiver burden. Particular care is needed when differentiating apathy from depression, as the two syndromes can often be confused in the population. Evaluating for sleep disturbance is also important. Comprehensive neuropsychiatric measures such as the NPI may help provide insight on all of these potential behavioral features.
